JP7792339B2 - コロナウイルスワクチン製剤 - Google Patents

コロナウイルスワクチン製剤

Info

Publication number
JP7792339B2
JP7792339B2 JP2022545141A JP2022545141A JP7792339B2 JP 7792339 B2 JP7792339 B2 JP 7792339B2 JP 2022545141 A JP2022545141 A JP 2022545141A JP 2022545141 A JP2022545141 A JP 2022545141A JP 7792339 B2 JP7792339 B2 JP 7792339B2
Authority
JP
Japan
Prior art keywords
cov
seq
amino acids
glycoprotein
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022545141A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023512648A5 (https=
JPWO2021154812A5 (https=
JP2023512648A (ja
Inventor
スミス，ゲイル
ジェイ． マサレ，マイケル
ティアン，ジン－フイ
Original Assignee
ノババックス，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US16/997,001 external-priority patent/US10953089B1/en
Application filed by ノババックス，インコーポレイテッド filed Critical ノババックス，インコーポレイテッド
Publication of JP2023512648A publication Critical patent/JP2023512648A/ja
Publication of JP2023512648A5 publication Critical patent/JP2023512648A5/ja
Publication of JPWO2021154812A5 publication Critical patent/JPWO2021154812A5/ja
Priority to JP2025184688A priority Critical patent/JP2026026092A/ja
Application granted granted Critical
Publication of JP7792339B2 publication Critical patent/JP7792339B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
JP2022545141A 2020-01-27 2021-01-27 コロナウイルスワクチン製剤 Active JP7792339B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025184688A JP2026026092A (ja) 2020-01-27 2025-10-31 コロナウイルスワクチン製剤

Applications Claiming Priority (17)

Application Number Priority Date Filing Date Title
US202062966271P 2020-01-27 2020-01-27
US62/966,271 2020-01-27
US202062976858P 2020-02-14 2020-02-14
US62/976,858 2020-02-14
US202062983180P 2020-02-28 2020-02-28
US62/983,180 2020-02-28
US202063048945P 2020-07-07 2020-07-07
US63/048,945 2020-07-07
US202063051706P 2020-07-14 2020-07-14
US63/051,706 2020-07-14
US202063054182P 2020-07-20 2020-07-20
US63/054,182 2020-07-20
US16/997,001 2020-08-19
US16/997,001 US10953089B1 (en) 2020-01-27 2020-08-19 Coronavirus vaccine formulations
US202063129392P 2020-12-22 2020-12-22
US63/129,392 2020-12-22
PCT/US2021/015220 WO2021154812A1 (en) 2020-01-27 2021-01-27 Coronavirus vaccine formulations

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025184688A Division JP2026026092A (ja) 2020-01-27 2025-10-31 コロナウイルスワクチン製剤

Publications (4)

Publication Number Publication Date
JP2023512648A JP2023512648A (ja) 2023-03-28
JP2023512648A5 JP2023512648A5 (https=) 2024-02-02
JPWO2021154812A5 JPWO2021154812A5 (https=) 2024-02-02
JP7792339B2 true JP7792339B2 (ja) 2025-12-25

Family

ID=77079351

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022545141A Active JP7792339B2 (ja) 2020-01-27 2021-01-27 コロナウイルスワクチン製剤
JP2025184688A Pending JP2026026092A (ja) 2020-01-27 2025-10-31 コロナウイルスワクチン製剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025184688A Pending JP2026026092A (ja) 2020-01-27 2025-10-31 コロナウイルスワクチン製剤

Country Status (14)

Country Link
US (1) US20230070886A1 (https=)
EP (1) EP4097123A4 (https=)
JP (2) JP7792339B2 (https=)
KR (1) KR20220141302A (https=)
CN (1) CN115720581A (https=)
AU (1) AU2021214064A1 (https=)
BR (1) BR112022014830A2 (https=)
CA (1) CA3165371A1 (https=)
GB (1) GB2610070A (https=)
IL (1) IL295142A (https=)
MX (1) MX2022009167A (https=)
TW (1) TW202142555A (https=)
WO (1) WO2021154812A1 (https=)
ZA (1) ZA202401922B (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10953089B1 (en) 2020-01-27 2021-03-23 Novavax, Inc. Coronavirus vaccine formulations
EP3901261A1 (en) 2020-04-22 2021-10-27 BioNTech RNA Pharmaceuticals GmbH Coronavirus vaccine
WO2021249116A1 (en) 2020-06-10 2021-12-16 Sichuan Clover Biopharmaceuticals, Inc. Coronavirus vaccine compositions, methods, and uses thereof
WO2021249011A1 (en) 2020-06-10 2021-12-16 Sichuan Clover Biopharmaceuticals, Inc. Hiv vaccine compositions, methods, and uses thereof
WO2022041760A1 (en) 2020-08-31 2022-03-03 Sichuan Clover Biopharmaceuticals, Inc. Methods and compositions for purification of trimeric fusion proteins
WO2022235663A1 (en) * 2021-05-05 2022-11-10 Novavax, Inc. Coronavirus and influenza compositions and methods for using them
CN113773372B (zh) * 2021-08-15 2024-08-02 北京科兴中维生物技术有限公司 重组蛋白及其制备方法和应用
CN116041448B (zh) * 2021-08-26 2025-05-13 江苏瑞科生物技术股份有限公司 新型冠状病毒免疫原性物质、其制备方法和应用
EP4436984A1 (en) * 2021-11-24 2024-10-02 Flagship Pioneering Innovations VI, LLC Coronavirus immunogen compositions and their uses
US12186387B2 (en) 2021-11-29 2025-01-07 BioNTech SE Coronavirus vaccine
KR20240125935A (ko) * 2021-11-30 2024-08-20 노바백스, 인코포레이티드 코로나바이러스 백신 제형물
CN114031675B (zh) * 2022-01-10 2022-06-07 广州市锐博生物科技有限公司 基于SARS-CoV-2的S蛋白的疫苗和组合物
WO2024002985A1 (en) 2022-06-26 2024-01-04 BioNTech SE Coronavirus vaccine
EP4709741A1 (en) * 2023-05-12 2026-03-18 Icosavax, Inc. Coronavirus spike glycoprotein receptor binding domains and uses thereof
US20250109187A1 (en) 2023-09-28 2025-04-03 Novavax, Inc. ANTI-SARS-CoV-2 SPIKE (S) ANTIBODIES AND THEIR USE IN TREATING COVID-19

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018081318A1 (en) 2016-10-25 2018-05-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Prefusion coronavirus spike proteins and their use
JP2018532703A (ja) 2015-09-03 2018-11-08 ノババックス，インコーポレイテッド 改善された安定性および免疫原性を有するワクチン組成物
CN111499692A (zh) 2020-06-16 2020-08-07 国家纳米科学中心 靶向新型冠状病毒covid-19的多肽及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1508615A1 (en) * 2003-08-18 2005-02-23 Amsterdam Institute of Viral Genomics B.V. Coronavirus, nucleic acid, protein, and methods for the generation of vaccine, medicaments and diagnostics
US20070124833A1 (en) * 2005-05-10 2007-05-31 Abad Mark S Genes and uses for plant improvement
JP5813513B2 (ja) * 2008-12-09 2015-11-17 ノババックス，インコーポレイテッド 修飾ｒｓｖｆタンパク質及びその使用方法
US20130122032A1 (en) * 2011-09-30 2013-05-16 Gale Smith Recombinant nanoparticle rsv f vaccine for respiratory syncytial virus
KR102399854B1 (ko) * 2013-09-19 2022-05-19 노바백스, 인코포레이티드 면역원성 중동호흡기증후군 코로나바이러스 (ΜＥＲＳ-ＣｏＶ) 조성물 및 방법
US20170354729A1 (en) * 2016-03-16 2017-12-14 Novavax, Inc. Vaccine compositions containing modified zika virus antigens
MA47790A (fr) * 2017-03-17 2021-05-05 Modernatx Inc Vaccins à base d'arn contre des maladies zoonotiques

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018532703A (ja) 2015-09-03 2018-11-08 ノババックス，インコーポレイテッド 改善された安定性および免疫原性を有するワクチン組成物
WO2018081318A1 (en) 2016-10-25 2018-05-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Prefusion coronavirus spike proteins and their use
CN111499692A (zh) 2020-06-16 2020-08-07 国家纳米科学中心 靶向新型冠状病毒covid-19的多肽及其应用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
GenBank :Wuhan seafood market pneumonia virus isolate Wuhan-Hu-1, complete genome, Accession no. MN908947.1 (GenBank)，GenBank，2020年01月12日

Also Published As

Publication number Publication date
CN115720581A (zh) 2023-02-28
BR112022014830A2 (pt) 2022-09-27
EP4097123A1 (en) 2022-12-07
IL295142A (en) 2022-09-01
TW202142555A (zh) 2021-11-16
JP2026026092A (ja) 2026-02-16
GB202212336D0 (en) 2022-10-12
ZA202401922B (en) 2025-04-30
GB2610070A (en) 2023-02-22
MX2022009167A (es) 2022-08-17
KR20220141302A (ko) 2022-10-19
US20230070886A1 (en) 2023-03-09
AU2021214064A1 (en) 2022-08-18
WO2021154812A8 (en) 2022-02-24
EP4097123A4 (en) 2024-02-14
WO2021154812A1 (en) 2021-08-05
JP2023512648A (ja) 2023-03-28
CA3165371A1 (en) 2021-08-05

Similar Documents

Publication Publication Date Title
JP7792339B2 (ja) コロナウイルスワクチン製剤
US11253586B2 (en) Coronavirus vaccine formulations
JP2024511412A (ja) コロナウイルスワクチン製剤
JP7783222B2 (ja) 呼吸器疾患を治療するための方法および組成物
KR20240125935A (ko) 코로나바이러스 백신 제형물
JP2026000942A (ja) Ｒｓｖ感染によって引き起こされる疾患又は障害を予防する方法
RU2845642C1 (ru) Вакцинные составы против коронавируса
HK40088999A (zh) 冠状病毒疫苗配制品
KR20250175335A (ko) Sars-cov-2 백신 조성물

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220927

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240125

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240125

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20241225

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250106

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250403

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250703

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251031

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20251125

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20251215

R150 Certificate of patent or registration of utility model

Ref document number: 7792339

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150